Tricida is a pharmaceutical company focused on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer designed to treat metabolic acidosis. Metabolic acidosis is a serious condition common caused by CKD that can result in accelerated progression of kidney disease.
In order to optimize our website for you and to be able to continuously improve it, we use cookies. By continuing to use the website, you agree to the use of cookies. Further information on cookies can be found in our Privacy Policy.
